-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 19, Stance Bio announced that the U.
According to public information, Stance Bio is focused on developing cellular immunotherapies for the treatment of solid tumors, and its unique CoupledCAR technology platform is designed to overcome common challenges in the treatment of solid tumors
Earlier, a clinical trial of 35 R/R mCRC patients with GCC19CART in China has achieved preliminary results
It is reported that the FDA granted Fast Track designation to GCC19CART based on its potential in the treatment of R/R mCRC patients who are ineffective in conventional therapy
Relapsed and refractory colorectal cancer, as recognized by the National Comprehensive Cancer Council (NCCN), is defined as patients who have failed multiple lines of standard therapy or who develop metastases and who have few effective treatment options
References:
[1] Gotecca Ecosystem | FDA grants Fast Track designation to Stansay Bio for colorectal cancer CAR-T therapy products.
[2] Gotega Ecosystem | Stanser Biotech completed over US$40 million in Series C financing, and CAR-T for solid tumors was approved by the US IND.
